We are live on
!
Find out more
AA
AlphaCentric Advisors Portfolio holdings
AUM
$100M
This Fund
S&P 500
This Quarter
Est. Return
-0.63%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$145M
AUM Growth
+$43.7M
(+43%)
Cap. Flow
+$49.2M
Cap. Flow
% of AUM
33.95%
Top 10 Holdings %
Top 10 Hldgs %
24.02%
Holding
223
New
58
Increased
36
Reduced
83
Closed
14
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares 1-3 Year Treasury Bond ETF
SHY
|
+$6.28M |
| 2 |
Centene
CNC
|
+$3.55M |
| 3 |
Harmony Biosciences
HRMY
|
+$3.07M |
| 4 |
BioCryst Pharmaceuticals
BCRX
|
+$2.84M |
| 5 |
Invesco QQQ Trust
QQQ
|
+$2.58M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Aurinia Pharmaceuticals
AUPH
|
+$2.42M |
| 2 |
PennyMac Financial
PFSI
|
+$1.76M |
| 3 |
AirSculpt Technologies
AIRS
|
+$1.33M |
| 4 |
Starwood Property Trust
STWD
|
+$1.19M |
| 5 |
Ametek
AME
|
+$1.05M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 56.03% |
| 2 | Real Estate | 10.47% |
| 3 | Financials | 4.37% |
| 4 | Energy | 4.28% |
| 5 | Technology | 3.06% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
76
Enact Holdings
ACT
$6.49B
| $580K | 0.4% |
25,367
| – | – |
|
77
Nuvation Bio
NUVB
$2.02B
| $573K | 0.4% |
345,000
+20,000
| +6% | +$40.5K |
|
78
iShares 3-7 Year Treasury Bond ETF
IEI
$18.2B
| $552K | 0.38% |
+4,695
| New | +$546K |
|
79
Sanofi
SNY
$107B
| $544K | 0.38% |
10,000
-10,000
| -50% | -$486K |
|
80
Valero Energy
VLO
$91.9B
| $542K | 0.37% |
3,883
-172
| -4% | -$23.1K |
|
81
Celldex Therapeutics
CLDX
$2.77B
| $540K | 0.37% |
15,000
| – | – |
|
82
BioMarin Pharmaceuticals
BMRN
$11.5B
| $535K | 0.37% |
+5,500
| New | +$570K |
|
83
Lennar Class A
LEN
$20.2B
| $512K | 0.35% |
5,028
| – | – |
|
|
NUVL
84
DELISTED
Nuvalent
NUVL
| $467K | 0.32% |
17,897
+2,397
| +15% | +$70.9K |
|
85
ExxonMobil
XOM
$611B
| $464K | 0.32% |
4,235
-184
| -4% | -$20.4K |
|
86
iShares JPMorgan EM High Yield Bond ETF
EMHY
$613M
| $464K | 0.32% |
+13,178
| New | +$469K |
|
87
Invesco Senior Loan ETF
BKLN
$7.19B
| $459K | 0.32% |
+22,066
| New | +$462K |
|
88
Knightscope
KSCP
$25.4M
| $445K | 0.31% |
10,000
+5,000
| +100% | +$329K |
|
89
Travere Therapeutics
TVTX
$5.27B
| $442K | 0.3% |
19,640
+1,000
| +5% | +$21.3K |
|
|
CTRA
90
DELISTED
Coterra Energy
CTRA
| $411K | 0.28% |
16,728
-878
| -5% | -$21.6K |
|
91
ConocoPhillips
COP
$140B
| $408K | 0.28% |
4,111
-171
| -4% | -$18.7K |
|
92
APA Corp
APA
$12.4B
| $399K | 0.28% |
11,062
-509
| -4% | -$20.4K |
|
|
RBOT
93
DELISTED
Vicarious Surgical
RBOT
| $397K | 0.27% |
5,833
+833
| +17% | +$64.8K |
|
94
Phillips 66
PSX
$82.9B
| $374K | 0.26% |
3,693
-150
| -4% | -$15.3K |
|
95
Diamondback Energy
FANG
$55B
| $371K | 0.26% |
2,744
-119
| -4% | -$16.6K |
|
96
Occidental Petroleum
OXY
$54.6B
| $354K | 0.24% |
5,663
-279
| -5% | -$17.3K |
|
|
SAFE
97
Safehold
SAFE
$1.22B
| $352K | 0.24% |
11,973
+3,874
| +48% | +$194K |
|
|
ASXC
98
DELISTED
Asensus Surgical, Inc.
ASXC
| $329K | 0.23% |
+500,000
| New | +$339K |
|
99
Medtronic
MDT
$106B
| $322K | 0.22% |
4,000
| – | – |
|
100
The Mosaic Company
MOS
$7.03B
| $322K | 0.22% |
7,026
-332
| -5% | -$16.1K |
|
Similar funds
WCM
FCM
BIA
AGAM
E
HCM
AC
OIS
AlphaCentric Advisors's Q1 2023 Portfolio in Review
As of Q1 2023, AlphaCentric Advisors held 223 positions worth $145M, up 43% from $101M the previous quarter. Its ten largest holdings account for 24% of the portfolio.
AlphaCentric Advisors deployed $49.2M of net new capital in Q1 2023, opening 58 new positions and adding to 36 existing holdings. Its largest new stake was iShares 1-3 Year Treasury Bond ETF: 76,992 shares worth $6.33M.
By sector, the portfolio is most concentrated in Healthcare at 56% of assets, down from 57% a quarter earlier, followed by Real Estate and Financials.
On the sell side, the largest reduction was Aurinia Pharmaceuticals, an estimated $2.42M trimmed.
- AlphaCentric Advisors's largest Q1 2023 buy was iShares 1-3 Year Treasury Bond ETF: 76,992 shares worth $6.33M.
- AlphaCentric Advisors added most to BioCryst Pharmaceuticals in Q1 2023, an estimated $2.84M increase.
- AlphaCentric Advisors's biggest Q1 2023 reduction was Aurinia Pharmaceuticals, cutting an estimated $2.42M.
- AlphaCentric Advisors fully exited PennyMac Financial in Q1 2023, selling an estimated $1.76M.
- AlphaCentric Advisors's ten largest holdings make up 24% of its $145M portfolio in Q1 2023.
- AlphaCentric Advisors opened 58 new positions and closed 14 in Q1 2023.
- AlphaCentric Advisors's portfolio value rose 43% quarter-over-quarter to $145M.
Based on AlphaCentric Advisors's 13F filing for Q1 2023, filed 12 May 2023.